| DB ID | MyCo_6480 |
| Title | Serum D-arabinitol measured by automated quantitative enzymatic assay for detection and therapeutic monitoring of experimental disseminated candidiasis: correlation with tissue concentrations of Candida albicans |
| Year | 1994 |
| PMID | 7965491 |
| Fungal Diseases involved | Disseminated candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | D-arabitino |
| Biomarker Full Name | D-arabitino |
| Biomarker Type | Diagnostic |
| Biomolecule | Metabolite |
| Geographical Location | USA |
| Cohort | Pathogen-free female New Zealand white rabbits (Hazleton, Rockville, MD) weighing 2-3 kg were used in all experiments. Animals were housed in individual cages, provided food and water ad libitum, and maintained in accordance with NIH guidelines on care and use of laboratory animals. Three groups of rabbits were studied: normal controls, untreated control rabbits with disseminated candidiasis and treated rabbits with disseminated candidiasis. Antifungal therapy consisted of different clinically applicable regimens to represent a range of therapeutic effects: amphotericin B 1 mg kg - 1 day - 1, amphotericin B 1 mg kg- 1 day - ~ plus 5-fluorocytosine, fluconazole 2 mg kg - l day- 1, SCH39304 2 mg kg- 1 day - I and cilofungin 50-90 mg kg - i day - 1. Among the animals studied, there were no significant differences among rabbits receiving specific antifungal regimens and thus all treated animals were studied as a group. |
| Cohort No. | 132 |
| Age Group | None |
| P Value | p< 0.0001 |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Disseminated candidiasis is an important cause of infectious morbidity and mortality in hospitalized patients. Unfortunately, disseminated candidiasis is also frequently difficult to detect by conventional culture-based laboratory methods. Moreover, once antifungal therapy is initiated for invasive candidiasis, therapeutic monitoring by laboratory methods is difficult and imprecise. For example: biopsies of tissue often cannot be repeated to document tissue clearance, positive blood cultures frequently clear even as deep tissue infection persists and diagnostic imaging modalities do not distinguish between inflammation and organisms. Thus far, there is no non-culture-based detection system for invasive candidiasis that is equivalent to the cryptococcal antigen detection system for laboratory diagnosis and therapeutic monitoring of cryptococcosis. |
| Technique | Analytic |
| Analysis Method | Rapid automated enzymatic assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Rapid automated enzymatic assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
